Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates

REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2023. “Throughout the first half of 2023, Adicet has achieved…
Click here to view original post